The paradigm of Huntington's disease: therapeutic opportunities in neurodegeneration
- PMID: 15717013
- PMCID: PMC534918
- DOI: 10.1602/neurorx.1.1.128
The paradigm of Huntington's disease: therapeutic opportunities in neurodegeneration
Abstract
Despite a relatively small number of affected patients, Huntington's disease (HD) has been a historically important disease, embodying many of the major themes in modern neuroscience, including molecular genetics, selective neuronal vulnerability, excitotoxicity, mitochondrial dysfunction, apoptosis, and transcriptional dysregulation. The discovery of the HD gene in 1993 opened the door to the mechanisms of HD pathogenesis. Multiple pathologic mechanisms have been discovered, each one serving as a potential therapeutic target. HD thus continues to serve as a paradigmatic disorder, with basic bench research generating clinically relevant insights and stimulating the development of therapeutic human trials.
Similar articles
-
Update on Huntington's disease.Curr Neurol Neurosci Rep. 2006 Jul;6(4):281-6. doi: 10.1007/s11910-006-0019-6. Curr Neurol Neurosci Rep. 2006. PMID: 16822347 Review.
-
[Huntington chorea. Animal models reveal new hypotheses for pathophysiology and therapy].Nervenarzt. 1999 Oct;70(10):878-88. doi: 10.1007/s001150050591. Nervenarzt. 1999. PMID: 10554779 Review. German.
-
Development of novel therapies for Huntington's disease: hope and challenge.Acta Pharmacol Sin. 2005 Feb;26(2):129-42. doi: 10.1111/j.1745-7254.2005.00520.x. Acta Pharmacol Sin. 2005. PMID: 15663888 Review.
-
Huntington's disease: pathogenesis to animal models.Pharmacol Rep. 2010 Jan-Feb;62(1):1-14. doi: 10.1016/s1734-1140(10)70238-3. Pharmacol Rep. 2010. PMID: 20360611 Review.
-
Selective neuronal degeneration in Huntington's disease.Curr Top Dev Biol. 2006;75:25-71. doi: 10.1016/S0070-2153(06)75002-5. Curr Top Dev Biol. 2006. PMID: 16984809 Review.
Cited by
-
Metabolomics-Based Identification of Metabolic Dysfunction in Frailty.J Gerontol A Biol Sci Med Sci. 2022 Dec 29;77(12):2367-2372. doi: 10.1093/gerona/glab315. J Gerontol A Biol Sci Med Sci. 2022. PMID: 36580380 Free PMC article.
-
Korean Red Ginseng Extract Attenuates 3-Nitropropionic Acid-Induced Huntington's-Like Symptoms.Evid Based Complement Alternat Med. 2013;2013:237207. doi: 10.1155/2013/237207. Epub 2013 Jan 27. Evid Based Complement Alternat Med. 2013. PMID: 23431333 Free PMC article.
-
Novel targets for Huntington's disease: future prospects.Degener Neurol Neuromuscul Dis. 2016 May 4;6:25-36. doi: 10.2147/DNND.S83808. eCollection 2016. Degener Neurol Neuromuscul Dis. 2016. PMID: 30050366 Free PMC article. Review.
-
3-Nitropropionic acid as a tool to study the mechanisms involved in Huntington's disease: past, present and future.Molecules. 2010 Feb 10;15(2):878-916. doi: 10.3390/molecules15020878. Molecules. 2010. PMID: 20335954 Free PMC article. Review.
-
Voxel-based morphometry indicates relative preservation of the limbic prefrontal cortex in early Huntington disease.J Neural Transm (Vienna). 2007 Mar;114(3):367-72. doi: 10.1007/s00702-006-0571-x. Epub 2006 Oct 6. J Neural Transm (Vienna). 2007. PMID: 17024326
References
-
- Housman D, Gusella JF. Application of recombinant DNA techniques to neurogenetic disorders. Res Publ Assoc Res Nerv Ment Dis 60: 167–172, 1983. - PubMed
-
- Gusella JF, Wexler NS, Conneally PM, Naylor SL, Anderson MA, Tanzi RE et al. A polymorphic DNA marker genetically linked to Huntington’s disease. Nature 306: 234–238, 1983. - PubMed
-
- Wexler NS, Rose EA, Housman DE. Molecular approaches to hereditary diseases of the nervous system: Huntington’s disease as a paradigm. Annu Rev Neurosci 14: 503–529, 1991. - PubMed
-
- Coyle JT, Schwarcz R. Lesion of striatal neurones with kainic acid provides a model for Huntington’s chorea. Nature 263: 244–246, 1976. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical